Hydroquinone is one of the most effective molecules for the treatment of hyperpigmentary disorders, with over 40 years of efficacy and safety data. Concerns over its safety have been raised because of the fact that it is a derivative of benzene and because of the long-term side-effects observed with cosmetic products containing high concentrations of hydroquinone. However, despite 40-50 years use of hydroquinone for medical conditions, there has not been a single documented case of either a cutaneous or internal malignancy associated with this drug. This article reviews the evidence for the safety of hydroquinone in the treatment of hyperpigmentation conditions.

No abstract

No abstract

One of the most distressing and difficult problems we encounter in the clinical setting is vitiligo in children and adolescents. In this symposium, several clinicians, some with a special interest in vitiligo, detail their approach to the treatment of this disorder in the pediatric age group.

Hypomelanosis of Ito appears to be a disorder of hypopigmentation. Findings from histochemical and electronmicroscopic studies indicate that pigment cells from the hypopigmented areas have short dendrites and synthesize less than normal amounts of melanin. The syndrome may have two forms; a cutaneous and neurocutaneous variety. In the more severe neurocutaneous variety, the phenotypic pigmentary abnormalities probably reflect a biochemical defect in all tissues derived from the neuro-ectodermal anlage.